Changes in Hong Kong stocks | Jietai Technology-P (07666) rose more than 33%, Moderna's major breakthrough opens up mRNA imagination space, and the company has the ability to develop mRNA cancer vaccines

The Zhitong Finance App learned that Jitai Technology-P (07666) surged more than 33%. As of press release, it had risen 31.74% to HK$15.44, with a turnover of HK$87.627 million.

According to the news, on August 19, Moderna and MSD announced that the phase III clinical trial of their jointly developed melanoma mRNA cancer vaccine had reached the main end, becoming the world's first clinically proven mRNA therapeutic cancer vaccine, confirming the viability and commercialization value of mRNA technology for cancer treatment. The news led to Moderna's stock price soaring 176.97%, and the market expects the domestic mRNA technology circuit's valuation system to be reshaped.

According to reports, Jietai Technology's AI enables the nanoForge platform for end-to-end mRNA design+LNP delivery+protein design, and also has mRNA tumor vaccine development capabilities+LNP delivery and sales capabilities. MTS-107 is the company's important pipeline in tumor treatment. The project explores HPV-related cancer treatment by delivering mRNA through LNP targeting the spleen and combining E6/E7 double antigen and immune activation mechanisms; MTS-105 uses the liver to target LNP to allow hepatocytes to produce and secrete TCE in situ in the body, and then enter tumor tissue to function.